GLP-1 Market
LLY $1181.89 ▲ +2.7% NVO $38.62 ▲ +1.2% PFE $28.41 ▲ +0.8% VKTX $36.75 ▼ -11.8% KLRA $11.98 ▼ -8.8% GPCR $36.02 ▲ +0.2% RHHBY $54.80 ▼ -0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

VERVE-102

VERVE-102

Company
Verve Therapeutics, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 25, 2026

Find a Clinical Trial Near Me

See recruiting studies for VERVE-102 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06164730

    A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

    Not yet reported Verve Therapeutics, Inc. 85 participants Est. completion 2027-10 27 sites Stand-alone
    Other conditions: Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
    View official trial listing →
  • Not yet recruiting NCT NCT07839936

    A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

    Not yet reported Verve Therapeutics, Inc. 175 participants Est. completion 2030-03 1 site Stand-alone
    Cardiovascular disease Other conditions: Atherosclerosis, Hypercholesterolemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: VERVE-102, LY4636581

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.